OnKure Therapeutics Statistics
Total Valuation
OKUR has a market cap or net worth of $111.79 million. The enterprise value is -$50.73 million.
Important Dates
The last earnings date was Wednesday, November 4, 2026, after market close.
| Earnings Date | Nov 4, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
OKUR has 40.50 million shares outstanding. The number of shares has increased by 139.12% in one year.
| Current Share Class | 40.50M |
| Shares Outstanding | 40.50M |
| Shares Change (YoY) | +139.12% |
| Shares Change (QoQ) | +0.12% |
| Owned by Insiders (%) | 10.22% |
| Owned by Institutions (%) | 49.26% |
| Float | 17.88M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 111.79 |
| PB Ratio | 0.71 |
| P/TBV Ratio | 0.71 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 18.84, with a Debt / Equity ratio of 0.01.
| Current Ratio | 18.84 |
| Quick Ratio | 18.58 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -10,998.33 |
Financial Efficiency
Return on equity (ROE) is -55.18% and return on invested capital (ROIC) is -36.56%.
| Return on Equity (ROE) | -55.18% |
| Return on Assets (ROA) | -34.38% |
| Return on Invested Capital (ROIC) | -36.56% |
| Return on Capital Employed (ROCE) | -41.69% |
| Weighted Average Cost of Capital (WACC) | 8.22% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.37M |
| Employee Count | 45 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -5.80% in the last 52 weeks. The beta is 0.73, so OKUR's price volatility has been lower than the market average.
| Beta (5Y) | 0.73 |
| 52-Week Price Change | -5.80% |
| 50-Day Moving Average | 2.68 |
| 200-Day Moving Average | 3.61 |
| Relative Strength Index (RSI) | 50.24 |
| Average Volume (20 Days) | 400,685 |
Short Selling Information
The latest short interest is 1.30 million, so 3.20% of the outstanding shares have been sold short.
| Short Interest | 1.30M |
| Short Previous Month | 1.39M |
| Short % of Shares Out | 3.20% |
| Short % of Float | 7.26% |
| Short Ratio (days to cover) | 2.89 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -65.99M |
| Pretax Income | -61.85M |
| Net Income | -61.85M |
| EBITDA | -65.64M |
| EBIT | -65.99M |
| Earnings Per Share (EPS) | -$1.94 |
Full Income Statement Balance Sheet
The company has $163.31 million in cash and $790,000 in debt, with a net cash position of $162.52 million or $4.01 per share.
| Cash & Cash Equivalents | 163.31M |
| Total Debt | 790,000 |
| Net Cash | 162.52M |
| Net Cash Per Share | $4.01 |
| Equity (Book Value) | 157.74M |
| Book Value Per Share | 3.89 |
| Working Capital | 156.80M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$47.89 million and capital expenditures -$49,000, giving a free cash flow of -$47.94 million.
| Operating Cash Flow | -47.89M |
| Capital Expenditures | -49,000 |
| Depreciation & Amortization | 348,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -47.94M |
| FCF Per Share | -$1.18 |
Full Cash Flow Statement Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
OKUR does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -139.12% |
| Shareholder Yield | -139.12% |
| Earnings Yield | -70.32% |
| FCF Yield | -42.88% |
Analyst Forecast
The average price target for OKUR is $15.25, which is 452.54% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $15.25 |
| Price Target Difference | 452.54% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |